{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:39:13Z","timestamp":1793255953502,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alkermes Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s40262-020-00969-w","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T04:22:46Z","timestamp":1607919766000},"page":"637-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8772-3217","authenticated-orcid":false,"given":"Lei","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"von Moltke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Rowland Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,14]]},"reference":[{"key":"969_CR1","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.bmcl.2009.02.078","volume":"19","author":"MP Wentland","year":"2009","unstructured":"Wentland MP, Lou R, Lu Q, et al. Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009;19:2289\u201394.","journal-title":"Bioorg Med Chem Lett."},{"key":"969_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1124\/jpet.118.249839","volume":"367","author":"JM Bidlack","year":"2018","unstructured":"Bidlack JM, Knapp BI, Deaver DR, et al. In vitro pharmacological characterization of buprenorphine, samidorphan, and combinations being developed as an adjunctive treatment of major depressive disorder. J Pharmacol Exp Ther. 2018;367:267\u201381.","journal-title":"J Pharmacol Exp Ther."},{"key":"969_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/JCP.0000000000000320","volume":"35","author":"MJ Shram","year":"2015","unstructured":"Shram MJ, Silverman B, Ehrich E, Sellers EM, Turncliff R. Use of remifentanil in a novel clinical paradigm to characterize onset and duration of opioid blockade by samidorphan, a potent mu-receptor antagonist. J Clin Psychopharmacol. 2015;35:242\u20139.","journal-title":"J Clin Psychopharmacol."},{"issue":"3","key":"969_CR4","first-page":"CD006654","volume":"17","author":"K Komossa","year":"2010","unstructured":"Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;17(3):CD006654.","journal-title":"Cochrane Database Syst Rev."},{"key":"969_CR5","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209\u201323.","journal-title":"N Engl J Med."},{"key":"969_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.euroneuro.2006.09.005","volume":"17","author":"JM Haro","year":"2007","unstructured":"Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007;17:235\u201344.","journal-title":"Eur Neuropsychopharmacol."},{"key":"969_CR7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951\u201362.","journal-title":"Lancet"},{"key":"969_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1017\/S0033291714001305","volume":"45","author":"A Yildiz","year":"2015","unstructured":"Yildiz A, Nikodem M, Vieta E, Correll CU, Baldessarini RJ. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med. 2015;45:299\u2013317.","journal-title":"Psychol Med."},{"key":"969_CR9","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","volume":"378","author":"A Cipriani","year":"2011","unstructured":"Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378:1306\u201315.","journal-title":"Lancet"},{"key":"969_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.4088\/JCP.10m06497","volume":"73","author":"RL Berkowitz","year":"2012","unstructured":"Berkowitz RL, Patel U, Ni Q, Parks JJ, Docherty JP. The impact of the clinical antipsychotic trials of intervention effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state. J Clin Psychiatry. 2012;73:498\u2013503.","journal-title":"J Clin Psychiatry."},{"key":"969_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","volume":"37","author":"JT Callaghan","year":"1999","unstructured":"Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177\u201393.","journal-title":"Clin Pharmacokinet."},{"key":"969_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.clinthera.2014.10.001","volume":"37","author":"R Turncliff","year":"2015","unstructured":"Turncliff R, DiPetrillo L, Silverman B, Ehrich E. Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers. Clin Ther. 2015;37:338\u201348.","journal-title":"Clin Ther."},{"key":"969_CR13","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.clinthera.2018.09.002","volume":"40","author":"L Sun","year":"2018","unstructured":"Sun L, McDonnell D, von Moltke L. Pharmacokinetics and short-term safety of ALKS 3831, a fixed-dose combination of olanzapine and samidorphan, in adult subjects with schizophrenia. Clin Ther. 2018;40:1845\u201354.","journal-title":"Clin Ther."},{"key":"969_CR14","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/cpdd.601","volume":"8","author":"L Sun","year":"2019","unstructured":"Sun L, McDonnell D, Liu J, von Moltke L. Bioequivalence of olanzapine given in combination with samidorphan as a bilayer tablet (ALKS 3831) compared with olanzapine-alone tablets: results from a randomized, crossover relative bioavailability study. Clin Pharmacol Drug Dev. 2019a;8:459\u201366.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"969_CR15","first-page":"81","volume":"25","author":"K Kassahun","year":"1997","unstructured":"Kassahun K, Mattiuz E, Nyhart E Jr, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos. 1997;25:81\u201393.","journal-title":"Drug Metab Dispos."},{"key":"969_CR16","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.2147\/DDDT.S205000","volume":"13","author":"L Sun","year":"2019","unstructured":"Sun L, Yagoda S, Du Y, Von Moltke L. Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet. Drug Des Devel Ther. 2019;13:2941\u201355.","journal-title":"Drug Des Devel Ther."},{"key":"969_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/1741-7015-11-263","volume":"11","author":"DJ Smith","year":"2013","unstructured":"Smith DJ, Martin D, McLean G, Langan J, Guthrie B, Mercer SW. Multimorbidity in bipolar disorder and undertreatment of cardiovascular disease: a cross sectional study. BMC Med. 2013;11:263.","journal-title":"BMC Med."},{"key":"969_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00406-013-0436-x","volume":"264","author":"D Schoepf","year":"2014","unstructured":"Schoepf D, Uppal H, Potluri R, Heun R. Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions. Eur Arch Psychiatry Clin Neurosci. 2014;264:3\u201328.","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"969_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1586\/ecp.10.143","volume":"4","author":"K Rowland Yeo","year":"2011","unstructured":"Rowland Yeo K, Aarabi M, Jamei M, Rostami-Hodjegan A. Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol. 2011;4:261\u201374.","journal-title":"Expert Rev Clin Pharmacol."},{"key":"969_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5414\/CPP38245","volume":"38","author":"R Yuan","year":"2000","unstructured":"Yuan R, Venitz J. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs. Int J Clin Pharmacol Ther. 2000;38:245\u201353.","journal-title":"Int J Clin Pharmacol Ther."},{"key":"969_CR21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/psp4.33","volume":"4","author":"C Wagner","year":"2015","unstructured":"Wagner C, Zhao P, Pan Y, et al. Application of physiologically based pharmacokinetic (PBPK) modeling to support dose selection: report of an FDA public workshop on PBPK. CPT Pharmacomet Syst Pharmacol. 2015;4:226\u201330.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"key":"969_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/psp4.12488","volume":"9","author":"L Sun","year":"2020","unstructured":"Sun L, von Moltke L, Rowland Yeo K. Physiologically-based pharmacokinetic modeling for predicting drug interactions of a combination of olanzapine and samidorphan. CPT Pharmacomet Syst Pharmacol. 2020;9:106\u201314.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"key":"969_CR23","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1211\/0022357043969","volume":"56","author":"AA El Ela","year":"2004","unstructured":"El Ela AA, Hartter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds: implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004;56:967\u201375.","journal-title":"J Pharm Pharmacol."},{"key":"969_CR24","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1124\/dmd.115.064790","volume":"43","author":"P Korprasertthaworn","year":"2015","unstructured":"Korprasertthaworn P, Polasek TM, Sorich MJ, et al. In vitro characterization of the human liver microsomal kinetics and reaction phenotyping of olanzapine metabolism. Drug Metab Dispos. 2015;43:1806\u201314.","journal-title":"Drug Metab Dispos."},{"key":"969_CR25","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/jps.20502","volume":"95","author":"T Rodgers","year":"2006","unstructured":"Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006;95:1238\u201357.","journal-title":"J Pharm Sci."},{"key":"969_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/jps.10005","volume":"91","author":"P Poulin","year":"2002","unstructured":"Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci. 2002;91:129\u201356.","journal-title":"J Pharm Sci."},{"key":"969_CR27","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1046\/j.1523-1755.1999.00411.x","volume":"55","author":"C Couchoud","year":"1999","unstructured":"Couchoud C, Pozet N, Labeeuw M, Pouteil-Noble C. Screening early renal failure: cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int. 1999;55:1878\u201384.","journal-title":"Kidney Int."},{"key":"969_CR28","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1046\/j.1523-1755.2001.059002725.x","volume":"59","author":"CY Hsu","year":"2001","unstructured":"Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Relationship between hematocrit and renal function in men and women. Kidney Int. 2001;59:725\u201331.","journal-title":"Kidney Int."},{"key":"969_CR29","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1681\/ASN.V132504","volume":"13","author":"CY Hsu","year":"2002","unstructured":"Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002;13:504\u201310.","journal-title":"J Am Soc Nephrol."},{"key":"969_CR30","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ki.1988.99","volume":"33","author":"R Vanholder","year":"1988","unstructured":"Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S. Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int. 1988;33:996\u20131004.","journal-title":"Kidney Int."},{"key":"969_CR31","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1208\/s12248-014-9626-3","volume":"16","author":"H Sayama","year":"2014","unstructured":"Sayama H, Takubo H, Komura H, Kogayu M, Iwaki M. Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients. AAPS J. 2014;16:1018\u201328.","journal-title":"AAPS J."},{"key":"969_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/cpdd.688","volume":"8","author":"L Sun","year":"2019","unstructured":"Sun L, McDonnell D, Liu J, von Moltke L. Effect of food on the pharmacokinetics of a combination of olanzapine and samidorphan. Clin Pharmacol Drug Dev. 2019b;8:503\u201310.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"969_CR33","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1210\/jc.2017-01922","volume":"102","author":"EJ Barrett","year":"2017","unstructured":"Barrett EJ, Liu Z, Khamaisi M, et al. Diabetic microvascular disease: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2017;102:4343\u2013410.","journal-title":"J Clin Endocrinol Metab."},{"key":"969_CR34","doi-asserted-by":"publisher","first-page":"109881","DOI":"10.1016\/j.pnpbp.2020.109881","volume":"100","author":"L Sun","year":"2020","unstructured":"Sun L, Yagoda S, Xue H, et al. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: results from a phase 1 QT\/QTc study. Prog Neuropsychopharmacol Biol Psychiatry. 2020;100:109881.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00969-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00969-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00969-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T03:38:05Z","timestamp":1620790685000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00969-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,14]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["969"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00969-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,14]]},"assertion":[{"value":"13 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Alkermes, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lei Sun is an employee of Alkermes, Inc. Lisa von Moltke was an employee of Alkermes, Inc. at the time of the study. Karen Rowland Yeo is an employee of Certara UK Limited, Simcyp Division.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The initial clinical study [] was conducted in accordance with the principles of the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guidelines, and local regulatory requirements. The study protocol was approved by the institutional review board or independent ethics committee at each study site.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All subjects provided written informed consent prior to study participation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The data collected in this study are proprietary to Alkermes, Inc. Alkermes, Inc. is committed to public sharing of data in accordance with applicable regulations and laws.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}}]}}